Future medicines discovery begins and ends with patients. Its scope will no longer be limited by the walls of the lab and the moats of major pharma. It will be disease-led, highly collaborative and fast.
Discovering & validating novel therapeutic targets to add to the immuno-oncology arsenal requires refined preclinical models that meet needs for suitability, scalability & clinical relevancy throughout the phases of target discovery & drug validation.
By Hannah Gitschier, Dr Ye Fang and Dr Richard M. Eglen
Past decades have witnessed significant efforts toward the development of 3D cell cultures. They are emerging not only as a new tool in early drug discovery, but also as potential therapeutics to treat disease.